Asco 2022 – Abbvie goes back to basics with navitoclax
Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.
Abbvie takes its Treg cue
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Ash 2021 – Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
